

Simulation and inference on purely observational methods of monitoring vaccine effectiveness post-deployment: none is reliable without precise information on population behaviour*

Roger Sewell

roger.sewell@cantab.net

July 18, 2023

Acknowledgements: I am grateful to Matt Jackson for pointing out that UK media don't all prefer the TNCC method, for detailed comments on the abstract, and for suggesting applying the model to partial real-world data; and to Stephen Mack for reviewing the main text.

Keywords: vaccine efficacy, Bayesian inference, uncertainty, confidence intervals, credible intervals, case-control studies, test-negative case-control, Bayes theorem.

Abstract

Two observational methods are currently being used to monitor post-deployment vaccine effectiveness against infection: the obvious crude method comparing rate of testing positive for infection per head of vaccinated population with that rate per head of unvaccinated population; and the test-negative case control (TNCC) method. The two methods give very different results. Various parties' preference for choice of method appears to broadly coincide with their vested interests in getting the result that method gives. We want to know whether either method is reliable.

We assume either a homogeneous population or one partitioned into two homogeneous subsets which differ only in their not-directly-observable healthcare-seeking behaviour including probability of getting vaccinated. We first consider uniform independent priors on the probabilities of being hospitalised conditional on subset, vaccination status, and infection status. We simulate from the resulting model and observe the TNCC estimate, the crude estimate, and the Bayesian central 95% confidence interval on vaccine effectiveness represented as log ratio of odds ratios for infection with and without vaccination. To show that such partial real-world data as is available leads to similar conclusions we also apply inference with the model to an example of real world data from 2021.

With these wide open priors, even when the population is homogeneous, the Bayesian 95% confidence interval typically has a width of nearly 4 nats (55-fold), implying too much uncertainty in the inference for the data currently collected to be of any use in monitoring vaccine effectiveness. While we do find that there exist some tight priors under which the data is useful, some lead to TNCC being more accurate (by around 5-fold based on standard deviation in the log domain) and with others the crude estimate is more accurate (by around 5 fold likewise).

Thus using only data from those spontaneously choosing to be tested, we find that neither TNCC nor the crude method is reliably better than the other, and indeed that the desired information is not present in this data. We conclude that effective post-deployment monitoring of vaccine effectiveness and side-effects requires either (a) strong information on the population's healthcare-seeking behaviour, (b) only

*Fourth version deposited in arxiv; RFS version 1.41.1.1 ; added conditional independence relationships and a third way to resolve the problem.

considering tests administered to a random sample of the population independent of their vaccination status and perceived state of health, or (c) ongoing randomised controlled trials (RCTs), rather than just choosing whichever of TNCC and crude estimate gives the result we prefer to find. We favour using RCTs.

Contents

1	Introduction	3
2	Intuitive description of methods	4
2.1	Measure of vaccine effectiveness	4
2.2	Estimates of vaccine effectiveness	4
2.3	Model	5
2.4	Priors	5
2.5	Exploration of the model	6
2.6	Partial real-life data	7
3	Results	7
3.1	The base case – wide open priors	7
3.2	The base case but with more patients	8
3.3	Prior 2 – With almost everybody in the same subset of the population	8
3.4	Prior 1 – Tight priors which make TNCC consistently better than the crude estimate	10
3.5	Prior 1 and more patients – Tight priors which make TNCC even better	10
3.6	Prior 3 – Tight priors which make TNCC worse than the crude estimate	10
3.7	With prior 0 and partial real-life data	12
3.8	Summary of results	12
4	Discussion	12
5	What should we do about it ?	13
A	Appendix - Definitions	14
A.1	Notation	14
A.2	Definitions of measures of vaccine effectiveness	14
A.3	Conditional independence relationships	15
B	Appendix - Model used and simulation and inference methods	17
B.1	Additional variable definitions	17
B.2	Model construction	17
B.3	Priors considered	18
B.4	Model evaluation and inference	18

1 Introduction

When doing post-marketing monitoring of efficacy of vaccines unexpected results are often obtained by collecting the obvious data, and the Test-Negative Case Control method (TNCC) is often put forward [1, 2] as a suitable method of ensuring that the biases thought to be responsible for these results are removed and the underlying vaccine efficacy made clear.

To take an example that is topical at the time of writing, in table 11 of [3] the United Kingdom Health Security Agency (UKHSA) reports raw data suggesting that the apparent rate of covid-19 infection in vaccinated 50-59 year olds is approximately double that in the corresponding unvaccinated population. In figure 1 of the same report they report data based on the TNCC method suggesting that, when the relevant biases are removed, the infection rate is between 45% and 95% lower in the vaccinated population than the unvaccinated. Or in another example, in the over-65s, [4] reports vaccine effectiveness (VE) values between 85% and 93% by TNCC while observing the raw rate of hospital admission for covid disease in the vaccinated to be 51% of that in unvaccinated individuals (and indeed the rate for vaccinated individuals for non-covid disease to be five times higher than for unvaccinated individuals)¹.

The TNCC method has been used since at least 1980 [5], and for monitoring influenza vaccine effectiveness in particular since at least 2005, and has been reviewed extensively in that context in [6] in 2016. As these latter authors make clear through the use of Bayesian networks represented by directed acyclic graphs (DAGs), it compensates perfectly for a situation where the population is divided into two groups, one of which always seeks healthcare when ill, while the other never seeks healthcare when ill. Where other covariates are measured, the combination of TNCC with logistic regression allows at least partial compensation for other variation within the population, e.g. age, comorbidity, etc. The same authors point out, as agreed in [7], that where the source of bias is not so binary and cut-and-dried there is no guarantee that bias due to variations in healthcare-seeking behaviour will be correctly handled.

Therefore the purpose of this paper is to investigate whether the TNCC method is more or less reliable than the crude method of estimating vaccine effectiveness in such a post-marketing situation, and indeed whether either method is at all suitable for this purpose. Even in the simple situation where the population is binarily divided into two groups, each of which has their own probabilities of seeking healthcare when ill with or without covid infection, we will suggest that neither method is adequate for the purpose, neither is free of bias, and that in fact the observational data itself does not contain the information sought to any useful degree of accuracy. We therefore suggest that in a post-marketing situation a randomly chosen subset of the population should be offered ongoing participation in a prospective randomised controlled study of vaccine versus placebo, without excluding any part of the population in which the vaccine is actually being used.

We first define intuitively the TNCC and the crude methods of observationally measuring vaccine effectiveness (VE), and how our model works (precise definitions and descriptions are given in the appendices). We describe the results under various different priors, then apply inference with the model to partial real-world data from [8], before discussing the implications and the actions we believe to be necessary.

Throughout we will refer to the disease being vaccinated against as “covid”, though there is nothing in the work reported other than the last-mentioned application to the data from [8] that is in any way specific to this particular disease.

¹Based on 10 million vaccinated and 600 thousand unvaccinated in the over-65s in the UK at the time, and the data in Table S12 of [4].

2 Intuitive description of methods

Full details of all definitions and methods are in appendices A and B. Here we attempt to give an intuitive description of what has been done.

2.1 Measure of vaccine effectiveness

The usual definition of vaccine effectiveness is

$$E = 1 - \frac{P(L|V)}{P(L|v)},$$

where L denotes the event that a patient has covid, V the event that they are vaccinated, v the event that they are not vaccinated, and $P(A|B)$ denotes the probability of A given B . In this paper we instead use the measure

$$T_0 = \log \left(\frac{P(L|V)}{1 - P(L|V)} / \frac{P(L|v)}{1 - P(L|v)} \right),$$

the log ratio of the odds of getting covid when vaccinated to the odds when not vaccinated. If the fraction of the population with covid is small then T_0 is approximately the same as $\log(1 - E)$; however, unlike $\log(1 - E)$, T_0 also notices when the probability of *not* getting covid is increased from a small value to a slightly larger one: see the examples in table 1.

$P(L v)$	$P(L V)$	$\log(1 - E)$	T_0
0.5	0.5	0	0
0.002	0.001	-0.693	-0.694
0.999	0.998	-0.001	-0.694
0.2	0.1	-0.693	-0.811
0.9	0.8	-0.118	-0.811
0.1	0.2	+0.693	+0.811

Table 1: Examples of the relationship between the probabilities of getting covid with and without vaccination and the corresponding values of E and T_0 .

In either case, a negative value of $\log(1 - E)$ or T_0 indicates the vaccine is effective, and a positive value indicates that the vaccine makes the recipient *more* likely to get covid than if he hadn't been vaccinated. The reasons for the choice of T_0 rather than E are that it makes the values returned by TNCC and/or the crude estimate correspond to T_0 in a manner that is easy to display and check without many samples accruing near zero or one and being hard to distinguish², and that it makes an increase in an initially small probability of avoiding infection easier to detect².

2.2 Estimates of vaccine effectiveness

T_1 will denote the corresponding estimate of vaccine effectiveness returned by the TNCC method; this is estimated by comparing the odds of having been vaccinated in those hospitalised with covid with the odds of having been vaccinated in those hospitalised without covid. In an idealised situation where everybody is always hospitalised for any illness T_1 will be very nearly equal to T_0 ; this will also be true in situations when the population divides into two subsets, one of which is always hospitalised for any illness and the other never [6]. Further, $T_1 = T_0$ if hospitalisation is conditionally independent of vaccination status given infection status, or if hospitalisation is conditionally independent of infection status given vaccination status – but neither of these is remotely likely to be true.

²While this may not be important in the case of covid, it may be very important for an always-fatal infection that one is very likely to get.

T_2 will denote the corresponding crude estimate of vaccine effectiveness that results from assuming that dividing the number of unvaccinated hospitalised covid cases by the number of unvaccinated people in the population gives an unbiased estimate of the infection rate in the unvaccinated (and similarly for the vaccinated). Again, if everybody is always hospitalised for every illness, T_2 will be very nearly equal to T_0 ; but in this case this will not be true if the population divides into two subsets with different healthcare-seeking behaviours – which is the reason why TNCC is often used. Moreover, if hospitalisation is conditionally independent of vaccination status given infection status, then again we will have $T_2 = T_0$.

What we are interested in is whether T_1 or T_2 is a better estimator of T_0 , and in whether the better of the two is a good enough estimator for practical use.

2.3 Model

Our model will divide the population into two homogeneous subsets (0 and 1) differing only in the non-directly-observable characteristic of the nature of their healthcare-seeking behaviour. The fraction of the population in subset 1 is given by p , an unknown on which we put a prior distribution (in the base case a uniform distribution on $[0, 1]$).

Each patient is then vaccinated with a probability r_s that depends on which subset s the patient is in; in the base case these two probabilities are again distributed uniformly and independently on $[0, 1]$. v will be 1 if the patient is vaccinated and 0 otherwise.

Each patient then does or doesn't acquire covid, with the probability of getting covid being j_v , depending on whether the patient has been vaccinated; then the variable l will be 1 if the patient gets covid, otherwise 0. Obviously one hopes that $j_1 < j_0$, but we don't assume this as we don't know whether this vaccine protects against covid or does the opposite (and we remind the reader that here "covid" means whatever disease the vaccine has been developed for). In the base case we therefore again put uniform independent priors on j_0 and j_1 .

Finally each patient does or doesn't get hospitalised ($h = 1$ or $h = 0$ respectively), with the probability of being hospitalised being $q_{s,l,v}$ and depending on which subset of the population the patient is in, whether or not they have covid, and whether or not they have been vaccinated. To keep our model simple we assume that a patient is tested for infection if and only if they get hospitalised. In particular $q_{s,0,1}$ denotes the probability that a patient in subset s who has been vaccinated and does not have covid gets hospitalised – whether from a vaccine induced injury or from intercurrent unrelated disease. In the base case we again put uniform independent priors on each of these eight variables $q_{s,l,v}$.

2.4 Priors

As noted above, in the base case all the 13 variables constituting p, r, j, q are given independent uniform priors, so that we can see what happens when these probabilities are all unknown; we name this **Prior 0**, or "wide open". We will also consider three other priors, which we name Priors 1, 2, and 3.

The full details of these priors are given in appendix section B.3. In both the base case and the variants the priors on j_v are both uniform on $[0, 1]$. In other respects the variants differ in ways whose intuitive descriptions are as follows:

Prior 1: The population divides into two roughly equal sized subsets. One subset mostly gets vaccinated, the other mostly not. The mostly-vaccinated subset almost always get hospitalised for any illness, while the mostly-unvaccinated subset only get hospitalised with probability 0.4 (independent of whether or not their illness is covid).

Prior 2: More than 99% of the population are in the larger of the two subsets; otherwise their behaviour is as in the base case.

Prior 3: Again more than 99% of the population are in the larger of the two subsets, and in both subsets individuals are vaccinated with probability 0.5. In either subset, if they either have covid or have been vaccinated they all almost always get hospitalised for any illness, but otherwise they are hospitalised with probability only 0.1 . (They might for example be scared by the fact that they have covid, or worried that they have a vaccine side-effect if they don't have covid but have been vaccinated.)

2.5 Exploration of the model

For each experiment we draw 20 random samples from the model. Each such sample includes values for each of the probabilities comprising p, r, j, q , and for each of the N patients draws values based on those probabilities for s, v, l, h . We then observe v and h for every patient, and l just for those patients who are hospitalised (who get tested for covid).

From these observations we can work out the estimates T_1 and T_2 of T_0 . From the value of j we can work out the true value $T_{0,\text{true}}$ of T_0 .

With far more effort we can draw samples of the Bayesian posterior distribution of T_0 using the methods described in appendix section B.4, which give us a picture of the possible range within which the true value of T_0 might lie. In particular we can determine the 2.5 and 97.5 centiles of that distribution, giving us a Bayesian confidence interval (a.k.a. credible interval) for T_0 , which is an interval in which, given the observed data, we are 95% sure that T_0 lies.

For the prior distribution in use for this experiment it is not possible for any other signal processing or analysis technique to improve on this posterior distribution. Therefore if the difference between the 2.5 and 97.5 centiles is (say) 4 nats³ then we are uncertain of the value of e^{T_0} , the ratio of odds ratios, to within a factor of $e^4 \approx 55$ -fold.

The relationships between $P(L|v)$, T_0 , and E are indicated in table 2.

$P(L v) = j_0$	T_0								
	-6	-4	-2	-1	0	1	2	4	6
0.01	99.7	98.2	86.3	63.0	0.0	-167.2	-594.5	-3454.6	-7929.6
0.05	99.7	98.1	85.9	62.0	-0.0	-150.3	-460.0	-1383.7	-1810.0
0.50	99.5	96.4	76.2	46.2	0.0	-46.2	-76.2	-96.4	-99.5
0.95	95.3	72.8	24.2	7.9	0.0	-3.3	-4.5	-5.2	-5.2
0.99	80.1	34.9	6.0	1.7	0.0	-0.6	-0.9	-1.0	-1.0

Table 2: Percentage values of vaccine effectiveness E corresponding to various combinations of $P(L|v)$ and T_0 .

For $j_0 = 0.5$ (half of unvaccinated patients get covid), for example, a difference of 4 nats in T_0 would be the difference between a vaccine having $T_0 = 0$ and $E = 0$ (makes no difference at all) and one which has $T_0 = -4$ and $E = 0.96$, i.e. is 96% effective; or e.g. between one which has $T_0 = -2$ and $E = 0.76$, i.e. is 76% effective and one which has $T_0 = +2$ and $E = -0.76$, i.e. one that increases the incidence of covid by 76%.

Equally if $j_0 = 0.05$ then it would be the difference between a vaccine having $T_0 = 0$ and $E = 0$ (vaccination makes no difference) and one having $T_0 = -4$ and $E = 0.98$ (98% effective), or between one having $T_0 = -2$ and $E = 0.86$ (86% effective) and one having $T_0 = +2$ and $E = -4.6$ (-460% effective, or increases infections by 460%).

An uncertainty of 4 nats in T_0 would therefore render the information obtained essentially useless.

³A "nat" is a difference of 1 for a natural logarithm to base e , and represents an e -fold difference in the quantity whose logarithm is being considered.

2.6 Partial real-life data

Instead of using synthetic data made from the model, we can also run the model using real-life data if available. In order to check that real-life data is not of a nature that results in a different inference conclusion, we applied inference using the model to the data from [8], indeed specifically to those who were either completely unvaccinated or had received two doses of the vaccine, and to those who either tested negative or were infected with the alpha variant of covid. Specifically this gave us the numbers shown in table 3 covering a total of $N = 127820$ patients seen in hospital and tested.

Vaccination status	Test status	
	Negative	Alpha positive
Unvaccinated	96371	7313
Vaccinated	23993	143

Table 3: Data on patients from table 2 of [8] who were tested either negative or positive for the alpha variant of covid, and who were either completely unvaccinated, or who had received two doses of any covid vaccine.

Now, the uses of the model described above all assume that the vaccination status of the entire population is known, even though the covid-test status is only known for those who are hospitalised. In the case of the real-life data from [8] we do not know the vaccination status of the entire population. Therefore we considered three possible assumptions about the unseen part of the population, in all cases assumed to number $2N$, namely:

Assumption 1: 19% of the unseen population is vaccinated (the same fraction as in those seen in hospital);

Assumption 2: The entire unseen population is vaccinated; or

Assumption 3: Half of the unseen population are vaccinated or unvaccinated in the same proportion to those seen in hospital, while the vaccination status of the remainder is unknown.

3 Results

In all cases the reader who prefers to see percentage values of E rather than plots of T_0 is referred to appendix D.

3.1 The base case – wide open priors

We start by looking at what happens in the base case when all the priors are uniform on $[0, 1]$ and we have $N = 1000$ patients (the default number except where stated otherwise). The results of the 20 random samples from the model are shown in figure 1. Where the red mark is nearer the green line than the cyan mark is, TNCC is more accurate than the crude estimate, and vice versa. The tiny blue dots are samples from the Bayesian posterior on T_0 , and where the two dark blue marks (the 2.5th and 97.5th centiles) are close together the data determines T_0 more accurately than when they are far apart.

We see from this that in this case there is essentially no difference in quality between the TNCC (T_1) estimate and the crude estimate (T_2) – both are fairly useless in determining vaccine efficacy, with errors of around 1.3 nats standard deviation. But, even though on average both of them are out by around 1.3 nats, the Bayesian confidence intervals obtained have a width of 3.8 nats on average, with some much wider than this – so that the results are essentially useless, even if the root-mean-square error is only 1.3 nats.




Figure 1: The results of using the base-case, wide-open prior, with $N = 1000$. If we do not know the values of the various probabilities comprising p, r, j, q and believe them to be equally likely to take any values in $[0, 1]$, then: about half the patients get hospitalised; of the 20 runs, 10 had T_1 more accurate than T_2 ; the standard deviation of the error was 1.29 nats for T_1 and 1.35 nats for T_2 ; and the difference between the 2.5th and 97.5th centiles of the posterior for T_0 was 3.8 nats on average.

Those interested in checking the plausibility of the samples giving the extreme values of T_0 are directed to appendix section C below.

3.2 The base case but with more patients

We wonder next whether the huge uncertainty in the inference might be because we don't have enough patients. We therefore increase the number of patients to $N = 10000$ patients, without changing the wide-open priors. The results are then shown in figure 2. Again, about half the patients get hospitalised, so we are not talking of very small numbers being observed.

Although the standard deviation of the TNCC error has fallen somewhat, the width of the Bayesian confidence intervals are still far too large to be of any practical use. Note also that ten thousand patients may not seem like that many, but given that we are considering relatively high hospitalisation rates, the data we are getting is probably comparable to a catchment population of a million or so in real life in the specific current covid situation.

3.3 Prior 2 – With almost everybody in the same subset of the population

In fact it turns out that we don't need two large subsets of the population to cause these problems. Using Prior 2, we get figure 3.

We again see that it is pot-luck which of TNCC or crude estimate does better, and that the Bayesian confidence intervals are still wide open on average.




Figure 2: The results of using the base-case, wide-open prior. If we do not know the values of the various probabilities comprising p, r, j, q and believe them to be equally likely to take any values in $[0, 1]$, but now have $N = 10000$ patients, then: of the 20 runs, 12 had T_1 more accurate than T_2 ; the standard deviation of the error was 0.94 nats for T_1 and 1.6 nats for T_2 ; and the difference between the 2.5th and 97.5th centiles of the posterior for T_0 was 3.4 nats on average.




Figure 3: The results of using Prior 2 with one subset containing $> 99\%$ of the population. Then: of the 20 runs, 13 had T_1 more accurate than T_2 ; the standard deviation of the error was 1.5 nats for T_1 and 2.4 nats for T_2 ; and the difference between the 2.5th and 97.5th centiles of the posterior for T_0 was 4.6 nats on average.

3.4 Prior 1 – Tight priors which make TNCC consistently better than the crude estimate

However, there are other settings of the priors which make the TNCC method consistently better than the crude estimate. Using Prior 1 we get figure 4.




Figure 4: The results of using Prior 1, using $N = 1000$ patients. Then: about 697 patients get hospitalised on average; of the 20 runs, 18 had T_1 more accurate than T_2 , with all the T_2 estimates being too high; the standard deviation of the error was 0.44 nats for T_1 and 1.96 nats for T_2 ; and the difference between the 2.5th and 97.5th centiles of the posterior for T_0 was 1.1 nats on average.

So in this case we are saying that we know the values of the various probabilities affecting whether people are vaccinated or not and whether or not they are hospitalised under the various circumstances, and that we know them fairly accurately. Then – having made this very strong assumption – TNCC is much better than the crude estimate, and moreover the Bayesian confidence interval is much narrower than with wide open priors. Indeed, the crude estimate is now often even some distance outside the Bayesian confidence interval.

3.5 Prior 1 and more patients – Tight priors which make TNCC even better

In this case we can do even better by looking at a larger number of patients. If we set $N = 10000$ and again use Prior 1, we get figure 5.

So in this case we are again saying that we know the values of the various probabilities affecting whether people are vaccinated or not and whether or not they are hospitalised under the various circumstances, and that we know them fairly accurately, and that we have a lot more patients (and a lot more being hospitalised). Then – having made this very strong assumption – TNCC is even better than it was with fewer patients, and moreover the Bayesian confidence interval is even narrower than with fewer patients.

3.6 Prior 3 – Tight priors which make TNCC worse than the crude estimate

However, it also entirely possible to have tight priors that make TNCC much *worse* than the crude estimate. If we use Prior 3, we get figure 6.




Figure 5: The results of using Prior 1 but now with $N = 10000$ patients. Then: of the 20 runs, all had T_1 more accurate than T_2 , with all the T_2 estimates being too high; the standard deviation of the error was 0.16 nats for T_1 and 1.9 nats for T_2 ; and the difference between the 2.5th and 97.5th centiles of the posterior for T_0 was 0.6 nats on average.




Figure 6: The results of using Prior 3 (with $N = 1000$ patients). Then: on average around 790 patients get hospitalised; of the 20 runs, *none* had T_1 more accurate than T_2 , with all the T_1 estimates being too low (i.e. suggesting vaccines are more effective than they are); the standard deviation of the error was 2.4 nats for T_1 and 0.71 nats for T_2 ; and the difference between the 2.5th and 97.5th centiles of the posterior for T_0 was 0.85 nats on average.

In this case we are again saying that we know the values of the various probabilities fairly accurately, but that they have different values than with the priors previously tried. In this case the crude estimate is far *better* than TNCC; indeed in every case TNCC is now way outside the Bayesian confidence interval.

3.7 With prior 0 and partial real-life data

Under the three possible assumptions on the unseen part of the population described in section 2.6, we obtained the results shown in table 4.

Assumption	T_1	T_2	T_0 2.5%ile	T_0 97.5%ile	N_{hosp}
1	-2.54	-2.49	-3.53	+3.11	127820
2	-2.54	-5.00	-4.79	+3.46	127820
3	-2.54	-2.49	-4.81	+0.41	127820

Table 4: Results of inference using real-life data as in table 3 and the three assumptions listed in section 2.6.

In all three cases, the width of the posterior distribution between the 2.5th and 97.5th centiles is greater than 5 nats, confirming that in this case also one cannot tell to any useful extent how effective the vaccine actually is.

3.8 Summary of results

Summarising the results, we see that the data obtained, with wide open priors, does not contain enough information to enable us to determine vaccine effectiveness to any useful extent, whether we use simulated or real-life data. Moreover there is very little to choose between the TNCC and crude estimates, which are each better than the other about half of the time, and increasing the number of patients does little to narrow the Bayesian confidence intervals.

On the other hand if we have solid information on the various prior probabilities comprising p, r, j, q , then, depending on those values, it may be that the TNCC method becomes far better than the crude method (and that the data then easily contains enough information about vaccine effectiveness to be useful) and improves still further with more patients; or on the other hand it may be such that the crude method becomes far better than the TNCC method (and again the data contains useful amounts of information).

Note, however, that we are *not* saying that where the crude method is right, TNCC is always too optimistic, or that where TNCC is right, the crude method is always too pessimistic. Indeed, the setup is symmetric in the l dimension, so if one swaps $l = 0$ and $l = 1$ in the relevant variant's prior the opposite error will become evident.

So in summary, unless we have priors that are both tight, and favourable to TNCC, TNCC is not reliably an improvement on the crude method – even if the population is essentially homogeneous. In the usual setting we do not have tight priors on these probabilities, let alone ones we know to be favourable to TNCC.

4 Discussion

We have shown that in the absence of informative priors, even in a homogenous population, data collected by monitoring rates of vaccinated and unvaccinated, covid-infected and uninfected, in only the hospitalised (or only the tested) population, along with whole population vaccination status, does not contain sufficient information to determine with any useful accuracy the extent to which vaccination

prevents infection. This is in no way a covid-specific finding, and indeed it has been theoretically foreseen in [6] and [7] years before the covid pandemic. Nonetheless, the same conclusions apply to real-life data collected in respect of the covid pandemic.

Neither the TNCC method nor the crude method is clearly better than the other; in some circumstances one is more accurate, and in others the other is more accurate, and we cannot tell which without knowing details of the population's behaviour that are very hard to measure – indeed in all circumstances where this behaviour remains unknown, neither method is useful to any appreciable extent.

Sadly we notice that there is a tendency to assume that the method giving the results we prefer is correct, for example in [3] and in daily BBC television news in the UK preferring the TNCC result indicating that vaccination is highly effective, while GB news (another UK TV channel) prefers the result of the crude method [9], indicating that vaccination actually increases the incidence of covid.

However these facts do not reduce the importance of ongoing monitoring of vaccine effectiveness and side effects. New variants of infectious agents arise frequently and may affect vaccine effectiveness; manufacturing changes may affect the incidence of side-effects, and even if not, when larger numbers are vaccinated more side-effects are likely to come to light. Even where individual side-effects are not statistically significant, the overall rate of serious side-effects may become both statistically significant and significant to the healthcare of the population.

5 What should we do about it ?

We can suggest two ways forward that do achieve reliable monitoring of vaccine effectiveness, both of which involve more work than just sitting back and waiting for data to flow to us:

1. Organise the testing randomly, independent of vaccination status or perception of being ill. By continually picking random members of the community to be tested, and then *exhaustively* ensuring that you get all the results back (whether they are at home / on holiday / in hospital) – which is a lot of work – you can ensure that being hospitalised (i.e. being tested) is conditionally independent of being vaccinated given your infection status ($h \perp v|l$), which as we show in appendix section A.3 ensures that you can easily deduce the vaccine effectiveness measure T_0 .
2. Do ongoing randomised controlled trials (RCTs) on a randomly chosen subset of the population. This obviously requires patient consent, and has the drawback (for those who believe a particular vaccine works well) that not everybody gets vaccinated that wants to be. Follow-up is again critical, which makes it hard work. It has, however, the big advantage that it also allows ongoing monitoring for side-effects which haven't been detected during the pre-deployment clinical trials.

Therefore it is our opinion that when vaccines are being given to large numbers of people it is important that ongoing double-blind, randomised, placebo-controlled clinical trials continue, as properly designed RCTs can avoid all the uncertainty to do with not knowing how patients decide to come forward for testing[10]. This can be done, for example, by enrolling (subject to informed consent) a randomly selected subset of the population for randomisation to vaccine or placebo and following them up long term. Such RCTs should not exclude any part of the population offered vaccination and able to give informed consent, lest the results fail to correctly represent actual practice. Further, they should be conducted by investigators unconnected with the commercial interests of the vaccine manufacturers or the political interests of the government and its advisers, and without any restriction on publication of the results.

In the specific case of the covid pandemic and the vaccines available as of mid 2022, it is notable that the trials undertaken ([11, 12, 13, 14]) have been of relatively low numbers and relatively short duration. Moreover the potential for ongoing collection of randomised data from at least [12] has been reduced by offering all the placebo-recipients vaccine when emergency authorisation of the vaccine was granted. There have also been a number of reports casting doubt on the validity of the results of these trials (e.g.

[15], [16]). The duration of any protection given by the vaccines, and their activity against variants, is also in doubt. The use of the TNCC method in ongoing monitoring is being preferred over the crude method without any justifying work showing that the underlying probabilities can be assumed to be sufficiently favourable to TNCC. We therefore think that it is especially important in this case that ongoing RCTs are undertaken.

A Appendix - Definitions

A.1 Notation

We define the following variables:

- v is the state of vaccination of a patient, 1 if vaccinated and 0 if not. If we want to refer to the vaccination state of patient n then we will refer to v_n , and similarly for the following variables.
- l is whether or not a patient is infected with covid, 1 if so, and 0 if not.
- h is whether or not a patient is hospitalised (i.e. tested), 1 if so, and 0 if not.
- s indicates which of two subsets 0 and 1 of the population a patient belongs to, which differ only in the not-directly-observable nature of their healthcare-seeking behaviour.

We assume throughout that, within each of the two s subsets of the population, the population is entirely homogeneous. This is of course a gross simplification in comparison with reality; but if, even with this simplification, the inference is uncertain, then it is reasonable to assume that it is uncertain in reality also. (Indeed our results show that inference is equally uncertain even if the population is almost entirely homogeneous rather than in two differing subsets.) Similarly we assume that being tested for covid is synonymous with being hospitalised.

To save symbols, we will use V to denote the state that $v = 1$, and use e.g. $P(V)$ to mean $P(V = 1)$ and $P(v)$ to mean $P(v = 0)$. Thus for example $P(vH|l)$ means the probability that a patient is hospitalised and hasn't been vaccinated given that they do not have covid.

The symbol $\#$ will denote one plus the number of individuals in a particular subset. For example, $\#LVH$ denotes one plus the number of individuals who have been vaccinated and are in hospital but do not have covid. (The reason for the "one plus" is so that e.g. $\frac{\#LV}{\#LV + \#LV}$ gives the posterior expectation of $P(L|V)$ given flat priors.)

A.2 Definitions of measures of vaccine effectiveness

We use the following further notation in relation to measures of vaccine effectiveness (all logarithms being natural, i.e. to base e):

- E , also denoted E_0 , is the usual definition of vaccine effectiveness, given by

$$E = 1 - \frac{P(L|V)}{P(L|v)}.$$

- T_0 is a slightly different measure of vaccine effectiveness, defined by

$$T_0 = \log \left(\frac{P(L|V)}{1 - P(L|V)} / \frac{P(L|v)}{1 - P(L|v)} \right),$$

the difference between the log odds of having covid if you are vaccinated and that log odds if you are unvaccinated. We note that also

$$T_0 = \log \left(\frac{P(L|V)}{P(l|V)} / \frac{P(L|v)}{P(l|v)} \right).$$

Thus a very negative value of T_0 goes with vaccination being effective, but T_0 will be the same if vaccination reduces the probability of getting covid from 0.2 to 0.1 as if it increases the probability of *not* getting covid from 0.1 to 0.2, unlike E , which changes much less in the latter situation. The reason for being interested in T_0 is that it intuitively corresponds closely with what is measured by TNCC. It is also easier to appreciate in plots when probabilities are close to zero or one.

- T_1 is what is measured by TNCC. If this were a non-homogeneous population in which various other covariates were also measured, it would be calculated by logistic regression, but in this population in which all directly observable characteristics are the same for everybody, simple division gives us what we need. We thus define

$$\begin{aligned} T_1 &= \log \left(\frac{\#LHV}{\#LHv} / \frac{\#lHV}{\#lHv} \right) \\ &= \log \left(\frac{\#LHV}{\#lHV} / \frac{\#LHv}{\#lHv} \right). \end{aligned}$$

Comparison of this with the definition of T_0 makes the intuitive correspondence clear.

- T_2 is the “obvious” crude estimate of T_0 , given by

$$T_2 = \log \left(\frac{\frac{\#LHV}{\#V} / \left(1 - \frac{\#LHV}{\#V}\right)}{\frac{\#LHv}{\#v} / \left(1 - \frac{\#LHv}{\#v}\right)} \right).$$

To get an intuitive feel for this, note that if we were going for estimating $1 - E$ rather than T_0 , we would instead be looking at

$$Q = \frac{\frac{\#LHV}{\#V}}{\frac{\#LHv}{\#v}},$$

the ratio of the infection rate in the vaccinated population to that in the unvaccinated. Thus T_2 is to T_0 for odds what Q is to $1 - E$ for probabilities.

- E_1 and E_2 respectively correspond to T_1 and T_2 as E_0 does to T_0 , using the equation below and the estimates of $P(L|v)$ given at the start of appendix D.

We note in passing that if we know the baseline probability $P(L|v)$ of an unvaccinated individual getting covid then we can determine either of E_0 and T_0 from the other, using the equation

$$E_0 = 1 - \frac{e^{T_0}}{1 + (e^{T_0} - 1)P(L|v)}.$$

A.3 Conditional independence relationships

We write $a \perp b|c$ to mean “ a is conditionally independent of b given c ”, and note the following points:

1. Considering the TNCC estimate T_1 :

$$\begin{aligned}
e^{T_1} &\approx \frac{P(LHV)}{P(lHV)} / \frac{P(LHv)}{P(lHv)} \\
&= \frac{P(H|LV)P(L|V)P(V)}{P(H|lV)P(l|V)P(V)} / \frac{P(H|Lv)P(L|v)P(v)}{P(H|lv)P(l|v)P(v)} \\
&= \frac{P(H|LV)P(H|lv)}{P(H|Lv)P(H|lV)} \left(\frac{P(L|V)}{P(l|V)} / \frac{P(L|v)}{P(l|v)} \right) \\
&= \frac{P(H|LV)P(H|lv)}{P(H|Lv)P(H|lV)} e^{T_0}
\end{aligned}$$

so that $T_0 = T_1$ if and only if

$$\frac{P(H|LV)P(H|lv)}{P(H|Lv)P(H|lV)} = 1,$$

which will be the case in particular if either $h \perp l|v$ or $h \perp v|l$, neither of which conditional independencies is remotely likely.

2. Similarly, let us assume that the vast majority of the vaccinated who are not both hospitalised and infected are in fact neither hospitalised nor infected, and similarly for the non-vaccinated, i.e. that

$$\begin{aligned}
P(lh|V) &\gg P(Lh|V) + P(lH|V) \\
P(lh|v) &\gg P(Lh|v) + P(lH|v),
\end{aligned}$$

which is of course true for most infectious diseases (and was even during the covid pandemic for covid). Then we find that $T_0 = T_2$ if and only if

$$\frac{P(H|LV)P(h|lv)}{P(h|lV)P(H|Lv)} = 1,$$

which again will be the case in particular if $h \perp v|l$, which is one of the same conditional independencies as in the previous point.

3. Now, the conditional independency that made $T_1 \approx T_0$ that doesn't achieve the same for $T_2 \approx T_0$ is $h \perp l|v$, i.e. that, both in the vaccinated and unvaccinated populations, getting hospitalised (i.e. tested) is independent of whether or not you are infected. It would be astonishing for this to be true.

So there is really nothing to choose between T_1 and T_2 in this regard, unless one has reason to believe that, in the absence of any conditional independencies, one of these ratios is more likely to be unity than the other.

4. Since in real life we observe different values of T_1 and T_2 , it follows that $h \not\perp v|l$.
5. If it were the case that $h \perp (l, v)$ then it would follow that $h \perp v|l$, and hence that $T_0 = T_1 = T_2$. Since we know that $h \not\perp v|l$, we also know that – at least spontaneously – we do not have $h \perp (l, v)$. However, it would be possible to collect a different dataset in which we did have $h \perp (l, v)$, remembering that the key point about the variable h here is that it measures whether the patient is *tested* for infection.

If, instead of just waiting for data to flow to us spontaneously, we deliberately send out tests to random members of the population (irrespective of vaccination status) and ensure that we get all the results back (which is really hard work !), then we would have a dataset in which $h \perp (l, v)$, which would provide one route forward to getting reliable monitoring data. It would then make no difference whether we analysed it believing it to be TNCC data or crude data.

B Appendix - Model used and simulation and inference methods

B.1 Additional variable definitions

We first make the following definitions of variables that are not directly observable:

- p is the probability that an individual belongs to the subset with $s = 1$, i.e. $p = P(S)$.
- $\alpha = (\alpha_0, \alpha_1)$ are parameters for a Beta prior distribution on p . Specifically

$$P(p|\alpha) = \frac{\Gamma(\alpha_0 + \alpha_1)}{\Gamma(\alpha_0)\Gamma(\alpha_1)}(1-p)^{\alpha_0-1}p^{\alpha_1-1},$$

where Γ denotes the Gamma function⁴. We note that in particular if $\alpha = (1, 1)$ then the prior on p is uniform on $[0, 1]$, and that if α_0 and α_1 are large then the prior is narrow with a mean of $\frac{\alpha_1}{\alpha_0 + \alpha_1}$.

- $r = (r_0, r_1)$ are the probabilities that an individual with $s = 0, 1$ respectively is vaccinated. Thus $r_0 = r_s = P(V|s)$.
- $\beta = ((\beta_{0,0}, \beta_{0,1}), (\beta_{1,0}, \beta_{1,1})) = ((\beta_{s,0}, \beta_{s,1}))_{s \in \{0,1\}}$ are the parameters for the Beta priors on r_0, r_1 respectively.
- $j = (j_0, j_1)$ are the probabilities that an individual who isn't or is vaccinated respectively gets covid. Thus $j_1 = j_V = P(L|V)$.
- $\gamma = ((\gamma_{0,0}, \gamma_{0,1}), (\gamma_{1,0}, \gamma_{1,1})) = ((\gamma_{v,0}, \gamma_{v,1}))_{v \in \{0,1\}}$ are the parameters for the Beta priors on j_0, j_1 respectively.
- $q = (q_{s,l,v})_{s,l,v \in \{0,1\}}$ are the probabilities that an individual with the given values of s, l , and v is hospitalised. For example $q_{0,0,1} = q_{sIV} = P(H|sIV)$.
- $\delta = ((\delta_{s,l,v,0}, \delta_{s,l,v,1}))_{s,l,v \in \{0,1\}}$ are the parameters for the Beta priors on the various components of q . Thus the parameters for the prior on q_{sIV} are $(\delta_{1,0,0,0}, \delta_{1,0,0,1})$.

B.2 Model construction

We simulate the population events over some fixed time period by generating random samples from the following model. For each sample we work out the true value of T_0 , the TNCC and crude estimates T_1 and T_2 , and take many (1000 or 10000) samples from the posterior distribution on T_0 to establish how accurately it is (or is not) possible to infer T_0 from the available data.

Intuitively we generate a random sample from our model by

- first drawing p from its Beta prior,
- then drawing s_n for each patient n from the discrete distribution on $\{0, 1\}$ with probability p of being 1, thus assigning each patient to one of the two subsets differing in healthcare-seeking behaviour;
- then drawing r (each component independently) from its Beta priors,
- then drawing v_n for each patient n from the discrete distribution on $\{0, 1\}$ with probability r_{s_n} of being 1, thus determining whether each patient gets vaccinated or not,

⁴For positive integers m , $\Gamma(m) = (m-1)!$; otherwise $\Gamma(x)$ is the natural mathematical extension of the function giving the factorial of $x-1$ to non-integers.

- then drawing j (each component independently) from its Beta priors,
- then drawing l_n for each patient n from the discrete distribution on $\{0, 1\}$ with probability j_{v_n} of being 1, thus determining whether each patient gets covid or not,
- then drawing q (each component independently) from its Beta priors,
- then drawing h_n for each patient n from the discrete distribution on $\{0, 1\}$ with probability q_{s_n, l_n, v_n} of being 1, thus determining whether each patient is hospitalised, dependent on their subset, covid-status, and vaccination-status.
- Finally we observe each patient’s vaccination status, and, for those who are hospitalised only, whether or not they have covid.

Mathematically we define a standard Bayesian generative model for N patients as follows: for $n = 1, \dots, N$:

$$\begin{aligned}
P(p|\alpha) &= \frac{\Gamma(\alpha_0 + \alpha_1)}{\Gamma(\alpha_0)\Gamma(\alpha_1)} (1-p)^{\alpha_0-1} p^{\alpha_1-1}; \\
P(S_n|p) &= p; \\
P(r_s|\beta_{s,0}, \beta_{s,1}) &= \frac{\Gamma(\beta_{s,0} + \beta_{s,1})}{\Gamma(\beta_{s,0})\Gamma(\beta_{s,1})} (1-r_s)^{\beta_{s,0}-1} r_s^{\beta_{s,1}-1}; \\
P(V_n|s_n, r_{s_n}) &= r_{s_n}; \\
P(j_v|\gamma_{v,0}, \gamma_{v,1}) &= \frac{\Gamma(\gamma_{v,0} + \gamma_{v,1})}{\Gamma(\gamma_{v,0})\Gamma(\gamma_{v,1})} (1-j_v)^{\gamma_{v,0}-1} j_v^{\gamma_{v,1}-1}; \\
P(L_n|v_n, j_{v_n}) &= j_{v_n}; \\
P(q_{s,l,v}|\delta_{s,l,v,0}, \delta_{s,l,v,1}) &= \frac{\Gamma(\delta_{s,l,v,0} + \delta_{s,l,v,1})}{\Gamma(\delta_{s,l,v,0})\Gamma(\delta_{s,l,v,1})} (1-q_{s,l,v})^{\delta_{s,l,v,0}-1} q_{s,l,v}^{\delta_{s,l,v,1}-1}; \\
P(H_n|s_n, l_n, v_n, q_{s_n, l_n, v_n}) &= q_{s_n, l_n, v_n};
\end{aligned}$$

where here the capitalised variables specifically denote the relevant variable being 1, while the lower case range over 0 and 1 consistently in each equation.

For the simulations we then consider the values of all v_n to be observed, along also with the values of l_n for those n for which $h_n = 1$. For some of the runs using partial real-world data from [8] we consider some of the values of v_n for which $h_n = 0$ to be unobserved, as described in the main text.

B.3 Priors considered

Table 5 gives the details of the various priors used. All are from the Beta family, and where a variable has several components, each is considered to be independently distributed; except where indicated otherwise all components have the same prior. Each prior is either uniform on $[0, 1]$ (i.e. has both parameters equal to 1) or has parameters summing to 200 such that $\frac{\theta_1}{\theta_0 + \theta_1}$ is equal to the value given which is then the mean of the distribution, where θ denotes either $\alpha, \beta_s, \gamma_v$, or $\delta_{s,l,v}$.

B.4 Model evaluation and inference

In order to then infer the posterior distribution on T_0 , we carry out Markov chain Monte Carlo Gibbs sampling, visiting the different unobserved variables (including those l_n for which $h_n = 0$) in palindromic order, maintaining detailed balance as we go. The details of how to do this are well described in [17], or see [18] or appendix 2 of [19]. To check convergence we compare the time-course and distribution of the various variables when started from values randomly generated by the model with the time-course and distribution when started from the true values that gave the observed data; in all cases these were

Prior Name	p	r_s	j_v	$q_{s,l,v}$
Wide open	uniform	uniform	uniform	uniform
Prior 1	0.5	0.005 ($s = 0$) 0.995 ($s = 1$)	uniform	0.4 ($s = 0$) 0.995 ($s = 1$)
Prior 2	0.995	uniform	uniform	uniform
Prior 3	0.995	0.5	uniform	0.995 ($l = 1$ or $v = 1$) 0.1 ($l = v = 0$)

Table 5: Definitions of the various Beta priors used. Where the prior is not uniform, the value given is the mean of the relevant Beta distribution, the sum of whose parameters is 200.

sufficiently similar not to change our conclusions. With $N = 1000$ patients, 1000 samples were sufficient for convergence, while with $N = 10000$ patients approximately 10000 samples were needed. For the real-world data with 127820 patients whose test results were known we used 200000 samples.

Having obtained each random sample from the model, we evaluate the corresponding value of T_0 by

$$T_0 = \log \left(\frac{j_1}{1 - j_1} / \frac{j_0}{1 - j_0} \right),$$

and similarly evaluate $T_{0,\text{true}}$ using the true values of j . The observed values of T_1 and T_2 can be calculated from their definitions by simply counting up the number of patients with each set of attributes. In the case of runs using real-world data from [8] in which some v_n are unobserved, we use the mean posterior value of the number of unvaccinated members of the population for calculating T_2 . The values of the centiles of T_0 are calculated as the centiles of the set of samples of T_0 after excluding the first 10% of samples as run-in, and similarly the centiles of E_0 and the posterior means of T_0 and E_0 .

C Appendix - Details of posterior samples giving high and low values of T_0

First, to illustrate that samples of j (and hence T_0) may vary greatly without the fractions of vaccinated patients or hospitalised patients in the population, or the fraction of covid-infected patients in the hospitalised population, varying very much, we show the time course of the sampled probabilities j in figure 7 and the time course of the calculated probabilities of V , H , and $L|H$ in figure 8 (all from the same run from which we consider specific samples below). This largely accounts for how it is possible to have huge uncertainty in inferring T_0 which isn't improved much by increasing the number of patients observed – the probabilities comprising p, r, j, q can, with broad priors, easily vary while keeping the probabilities of the observed data largely unchanged.

Second, to check plausibility of the results in figure 1 of section 3.1 we give specific examples giving high and low samples of T_0 from the posterior.

Specifically we look at the samples contributing to the specific posterior distribution shown in figure 1 with $T_{0,\text{true}} = -2.811$, where the 2.5th centile is at -7.804 and the 97.5th centile at +0.284. In this particular case the truth is that vaccination is moderately protective, the crude method gives very nearly the right result ($T_2 = -2.68$), and TNCC is very over-optimistic with $T_1 = -4.81$.

The values of the various probabilities giving the maximum sample of T_0 are shown in table 6 and those giving the minimum sample of T_0 are shown in table 7; in both cases a verbal description and possible reasons for the values seen are in the caption.




Figure 7: The time-course of successive MCMC samples of j , showing how widely they vary, despite the relative constancy of the calculated near-observable probabilities in figure 8. The dotted lines indicate the true values.




Figure 8: The time-course of the probabilities of the observable variables showing how near constant they are, despite the widely varying sample probabilities in figure 7.

T0true is -2.811

Maximum T0 is at sample 11 and is 1.548

p = 0.878

r = 0.668, 0.896

j = 0.386, 0.747

q:

for s=0:

v=0 v=1

l=0: 0.070, 0.704

l=1: 0.054, 0.007

for s=1:

v=0 v=1

l=0: 0.008, 0.782

l=1: 0.364, 0.018

Table 6: Details of the sample contributing to the run in figure 1 with $T_{0,\text{true}} = -2.811$ and the maximum sample of T_0 from the posterior. In this case we have $j_V > j_v$ indicating that vaccination makes it *more* likely you will get covid (hence the high $T_0 > 0$). The values of q say that in both groups people with non-covid illness are more likely to be hospitalised if they are vaccinated than if unvaccinated; this could be because of vaccine-induced injury, or because the vaccinated tend to seek healthcare more than the unvaccinated. In contrast those with covid are less likely to be hospitalised if vaccinated, perhaps because vaccination protects against hospitalisation but not against infection.

T0true is -2.811

Minimum T0 is at sample 492 and is -10.832

p = 0.946

r = 0.573, 0.883

j = 0.999, 0.017

q:

for s=0:

v=0 v=1

l=0: 0.009, 0.848

l=1: 0.246, 0.561

for s=1:

v=0 v=1

l=0: 0.853, 0.187

l=1: 0.168, 0.892

Table 7: Details of the sample contributing to the run in figure 1 with $T_{0,\text{true}} = -2.811$ and the minimum sample of T_0 from the posterior. In this case we have $j_V < j_v$, indicating that vaccination protects against infection. Most patients are in group 1 (as $p = 0.946$). In group 1 the values of q indicate that patients with covid are *more* likely to be hospitalised if vaccinated, perhaps because of vaccine-induced disease enhancement, while patients without covid are less likely to be admitted if vaccinated, perhaps because they are less worried by the possibility that they might get covid.

D Appendix – Values of E corresponding to figures 1 – 6 and table 4

This section lists the values of the traditional vaccine effectiveness values as percentages for the truth E_{true} , the TNCC estimate E_1 , the crude estimate E_2 , and the Bayesian 2.5th and 97.5th posterior centiles. In each table the runs are sorted by the true value of T_0 in order to be able to relate them to the corresponding items on the plots. The first two columns of each table give the true value of T_0 and the simulated value of $P(L|v)$ for that particular run.

Note, however, that the true value of $P(L|v)$ is not available to the estimates, so that E_1 uses the estimate $\frac{\#LHv}{\#LHv+\#lHv}$, E_2 uses the estimate $\frac{\#LHv}{1+\#v}$, and the Bayesian centiles come from directly calculated values of E_0 for each sample.

$T_{0,\text{true}}$	$P(L v)_{\text{true}}$	E_{true}	E_1	E_2	Bayes 2.5%	Bayes 97.5%	N_{hosp}
-3.074	0.710	85.679	87.073	82.130	56.083	89.522	776
-2.811	0.953	42.287	93.590	91.957	-24.365	98.529	216
-2.733	0.852	68.037	72.487	49.826	3.245	79.283	328
-2.417	0.623	79.397	86.691	71.249	-137.775	90.977	228
-2.089	0.750	63.931	74.134	72.411	42.955	78.476	682
-1.110	0.373	56.086	-969.141	-1208.564	-3663.482	78.842	189
-0.332	0.811	6.920	16.220	47.658	-81.462	48.599	382
-0.312	0.372	18.680	-23.207	-52.304	-147.062	58.318	470
-0.144	0.832	2.534	21.991	40.760	-72.299	71.055	404
0.140	0.318	-9.806	-25.147	29.165	-278.796	41.253	509
0.141	0.209	-11.576	-124.738	-81.882	-408.448	59.018	566
0.288	0.764	-6.288	-12.918	-15.516	-268.336	31.548	310
0.472	0.084	-52.644	-4.015	-66.959	-312.131	77.324	615
0.709	0.629	-23.231	-103.853	-153.800	-397.517	18.837	503
1.084	0.172	-121.368	-18.078	-73.009	-82.810	34.445	844
1.249	0.182	-140.176	-145.271	-338.073	-245.874	18.932	531
1.279	0.117	-175.917	-223.156	-437.778	-1244.194	56.445	556
1.332	0.153	-165.567	-3138.272	-2473.715	-8426.283	-106.109	768
2.387	0.195	-271.490	-255.245	-186.354	-388.993	-43.838	649
3.613	0.176	-403.744	-256.909	-70.470	-732.944	-82.719	447

Table 8: Vaccine effectiveness (E , %) values for each run shown in figure 1 corresponding to truth, TNCC, crude estimate, and the Bayesian 2.5th and 97.5th centiles of the posterior for T_0 .

$T_{0,\text{true}}$	$P(L v)_{\text{true}}$	E_{true}	E_1	E_2	Bayes 2.5%	Bayes 97.5%	N_{hosp}
-5.323	0.840	97.032	95.640	93.629	37.582	97.316	4320
-4.694	0.984	63.263	72.943	70.861	32.001	85.932	4303
-2.929	0.913	60.591	58.247	63.367	10.578	73.863	5694
-2.648	0.475	87.330	85.178	68.016	-126.789	93.423	3696
-2.414	0.676	76.727	80.734	68.697	64.482	83.411	8119
-2.285	0.852	56.605	77.974	74.986	36.707	86.546	5229
-2.136	0.877	47.786	67.563	32.371	26.499	73.487	4708
-1.859	0.471	74.158	80.600	79.880	-6.115	88.023	6961
-0.938	0.418	47.490	4.737	-100.291	-268.590	55.145	6419
-0.487	0.212	33.069	-586.910	-545.671	-1568.546	-6.846	4394
-0.032	0.065	2.969	-15.644	54.399	-363.605	77.810	4978
0.452	0.424	-26.464	-7.999	34.606	-73.243	36.370	7202
0.507	0.226	-44.476	-10.675	82.473	-194.850	82.507	5673
0.709	0.629	-23.231	-96.972	-155.118	-238.697	5.643	5272
1.416	0.506	-59.808	-184.106	-178.019	-231.968	-77.378	6875
1.617	0.578	-51.119	-46.292	50.894	-123.061	68.524	4173
1.955	0.319	-140.780	-72.071	-624.186	-981.407	-0.144	3203
2.050	0.323	-143.599	-31.527	-56.236	-177.652	19.011	4550
2.368	0.066	-552.585	-198.120	-304.273	-821.188	46.428	4877
5.182	0.016	-4654.035	-3187.130	-6954.207	-8025.957	-178.579	5348

Table 9: Vaccine effectiveness (E , %) values for each run shown in figure 2 corresponding to truth, TNCC, crude estimate, and the Bayesian 2.5th and 97.5th centiles of the posterior for T_0 .

$T_{0,\text{true}}$	$P(L v)_{\text{true}}$	E_{true}	E_1	E_2	Bayes 2.5%	Bayes 97.5%	N_{hosp}
-3.241	0.775	84.677	86.052	90.246	50.718	91.565	632
-3.102	0.887	70.565	73.177	17.053	53.642	76.278	768
-2.290	0.323	85.721	77.985	81.421	-245.818	91.606	273
-2.068	0.399	80.578	91.767	84.117	42.121	94.678	922
-1.836	0.699	61.383	3.424	-86.894	-214.846	94.521	369
-1.717	0.960	15.416	6.478	-718.851	-220.415	55.120	119
-1.444	0.419	65.287	47.412	31.686	-18.482	78.275	466
-1.167	0.413	56.491	47.637	50.346	-17.220	62.671	794
-0.838	0.887	12.870	-83.351	-820.894	-1033.070	7.428	679
-0.044	0.233	3.359	-209.900	-98.746	-446.878	39.824	558
0.046	0.591	-1.886	22.118	36.131	-6.122	57.717	608
0.187	0.733	-4.771	11.021	75.733	-15.422	77.879	200
0.615	0.514	-28.711	-95.077	-163.170	-164.313	-20.107	648
1.016	0.148	-119.117	-81.868	72.837	-585.205	91.567	666
1.452	0.234	-141.960	83.206	95.855	-4100.312	36.774	262
1.727	0.029	-396.603	-991.667	-1221.273	-1608.374	91.670	235
1.748	0.063	-341.544	-342.359	-547.313	-1192.383	48.411	580
2.267	0.684	-39.463	-8.218	-57.621	-79.587	1.403	946
4.107	0.012	-3492.194	-8227.568	-1862.944	-20366.003	-1728.672	519
5.511	0.066	-1326.968	-1237.600	-74.263	-1003.423	79.109	467

Table 10: Vaccine effectiveness (E , %) values for each run shown in figure 3 corresponding to truth, TNCC, crude estimate, and the Bayesian 2.5th and 97.5th centiles of the posterior for T_0 .

$T_{0,\text{true}}$	$P(L v)_{\text{true}}$	E_{true}	E_1	E_2	Bayes 2.5%	Bayes 97.5%	N_{hosp}
-7.010	0.996	83.049	81.166	57.440	77.896	84.463	677
-2.446	0.932	41.659	46.092	-38.647	41.406	50.690	713
-1.884	0.724	60.600	64.722	23.505	58.465	70.133	703
-1.533	0.109	76.382	75.208	39.189	57.085	86.903	674
-0.891	0.495	42.040	48.369	-27.738	37.268	57.713	662
-0.861	0.472	41.908	23.387	-80.493	2.731	40.895	736
-0.323	0.746	8.824	0.078	-145.494	-13.428	11.202	697
-0.282	0.423	15.824	17.889	-122.686	-6.651	34.081	695
-0.072	0.211	5.578	-8.134	-175.723	-66.488	22.612	701
0.148	0.053	-15.007	60.607	-11.625	19.171	77.653	662
0.281	0.748	-6.588	-9.331	-170.250	-20.523	-0.381	695
0.296	0.565	-12.579	-5.699	-128.836	-28.103	8.668	741
0.353	0.597	-13.596	-6.247	-175.058	-26.495	8.581	715
0.461	0.231	-39.591	-18.828	-192.822	-63.476	11.420	703
1.453	0.477	-66.950	-72.127	-327.003	-104.348	-43.129	680
1.567	0.333	-111.813	-150.507	-445.982	-225.309	-96.712	672
1.591	0.692	-32.450	-22.656	-189.307	-36.365	-12.549	712
2.132	0.158	-287.524	-654.600	-1834.200	-1450.494	-359.874	753
2.923	0.236	-260.594	-306.154	-970.408	-494.422	-207.465	693
4.623	0.032	-2329.143	-1613.424	-4356.143	-3817.201	-858.843	651

Table 11: Vaccine effectiveness (E , %) values for each run shown in figure 4 corresponding to truth, TNCC, crude estimate, and the Bayesian 2.5th and 97.5th centiles of the posterior for T_0 .

$T_{0,\text{true}}$	$P(L v)_{\text{true}}$	E_{true}	E_1	E_2	Bayes 2.5%	Bayes 97.5%	N_{hosp}
-3.732	0.634	93.722	94.079	84.328	93.151	95.133	6520
-2.529	0.309	88.858	89.610	75.642	87.741	91.733	7253
-2.484	0.402	86.787	88.381	70.316	85.010	89.951	6880
-2.239	0.993	5.709	6.649	-120.503	5.750	7.548	6741
-1.307	0.451	59.665	62.298	8.423	56.807	67.505	6953
-1.278	0.304	64.314	64.383	15.461	58.471	71.697	7040
-1.252	0.908	18.606	18.278	-98.120	15.488	20.346	6771
-0.999	0.363	52.214	49.184	-27.765	38.659	56.818	7141
-0.982	0.423	49.044	48.812	-26.332	39.327	56.453	7362
-0.883	0.533	39.844	41.428	-61.820	33.721	47.559	6732
-0.677	0.658	24.886	29.810	-94.370	25.507	35.262	7056
-0.565	0.854	9.993	10.366	-108.529	5.924	12.382	6822
-0.169	0.445	9.277	11.907	-135.263	-8.819	24.917	6769
0.263	0.735	-6.529	-12.397	-184.982	-21.206	-5.665	6995
0.327	0.844	-4.545	-4.249	-143.990	-9.198	-0.827	6649
0.521	0.809	-8.407	-9.639	-175.911	-15.457	-4.683	6532
0.890	0.019	-137.030	-64.789	-324.022	-141.645	-23.710	6761
1.636	0.662	-37.328	-39.671	-248.139	-53.268	-31.535	7148
2.132	0.158	-287.524	-299.566	-908.024	-401.116	-219.834	7497
5.250	0.711	-40.359	-34.858	-248.474	-41.094	-26.099	6787

Table 12: Vaccine effectiveness (E , %) values for each run shown in figure 5 corresponding to truth, TNCC, crude estimate, and the Bayesian 2.5th and 97.5th centiles of the posterior for T_0 .

$T_{0,\text{true}}$	$P(L v)_{\text{true}}$	E_{true}	E_1	E_2	Bayes 2.5%	Bayes 97.5%	N_{hosp}
-3.376	0.940	62.853	66.303	64.809	59.614	68.364	969
-2.308	0.822	61.681	66.420	59.239	53.676	64.287	906
-1.072	0.432	52.202	80.137	56.796	46.779	65.238	734
-0.858	0.890	12.951	20.380	11.856	6.066	16.209	952
-0.778	0.299	45.192	80.474	44.283	30.447	56.173	658
0.520	0.294	-40.083	52.804	-24.963	-52.152	-6.494	719
0.546	0.507	-26.194	23.196	-39.530	-55.869	-23.624	786
0.720	0.635	-23.102	12.756	-26.887	-36.252	-16.690	837
1.404	0.382	-87.406	8.868	-99.850	-124.598	-75.480	733
1.461	0.745	-24.339	5.409	-26.526	-33.467	-19.013	863
1.651	0.613	-45.518	4.762	-43.508	-55.745	-34.639	808
1.726	0.739	-27.351	5.127	-29.414	-37.998	-21.800	843
1.900	0.324	-135.031	0.098	-183.903	-234.442	-141.947	693
2.161	0.326	-147.737	-2.670	-139.846	-173.053	-109.532	736
2.186	0.280	-177.197	7.157	-159.727	-202.262	-124.833	691
2.201	0.447	-96.730	-0.500	-101.393	-126.738	-81.903	755
2.352	0.556	-67.187	-0.076	-59.844	-76.711	-48.576	820
3.413	0.100	-669.652	-26.932	-581.962	-762.468	-444.741	568
3.561	0.770	-28.747	-0.848	-29.128	-34.445	-22.099	884
7.070	0.651	-53.545	-4.471	-58.627	-71.408	-48.897	835

Table 13: Vaccine effectiveness (E , %) values for each run shown in figure 6 corresponding to truth, TNCC, crude estimate, and the Bayesian 2.5th and 97.5th centiles of the posterior for T_0 .

Assumption	Vaccine effectiveness (percentages)				N_{hosp}
	E_1	E_2	Bayes 2.5%	Bayes 97.5%	
1	91.5	91.5	-121	+96.8	127820
2	91.5	99.3	-902	+99.1	127820
3	91.5	91.5	-48.2	+98.9	127820

Table 14: Vaccine effectiveness (E , %) values using real-life data as in table 3 and the three assumptions listed in section 2.6.

References

- [1] Huiying Chua, Shuo Feng, et. al., “The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology,” *Epidemiology*, vol. 31, no. 1, pp. 43–64, 2020.
- [2] F. C. M. Kirsebom, N. Andrews, J. Stowe, S. Toffa, R. Sachdeva, E. Gallagher, N. Groves, A.-M. O’Connell, M. Chand, M. Ramsay, and J. L. Bernal, “Covid-19 vaccine effectiveness against the omicron (ba.2) variant in england,” *The Lancet Infectious Diseases*, vol. 22, no. 7, pp. 931–933, 2022.
- [3] U.K Health Security Agency, “COVID-19 vaccine surveillance report - Week 48.” https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1037987/Vaccine-surveillance-report-week-48.pdf, 2021. Retrieved on 28.6.2022.
- [4] Julia Stowe, Nick Andrews, Freja Kirsebom, Mary Ramsay, Jamie Lopez Bernal , “ Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study .” <https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full-text>, 2022. Retrieved on 28.6.2022.
- [5] Broome CV, Facklam RR, Fraser DW, “Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine,” *New England Journal of Medicine*, vol. 303, no. 10, pp. 549–552, 1980.
- [6] Sheena G. Sullivan, Eric J. Tchetgen Tchetgen, and Benjamin J. Cowling, “Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness,” *American Journal of Epidemiology*, vol. 184, no. 5, pp. 345–353, 2016.
- [7] Daniel Westreich and Michael G. Hudgens, “Beware the Test-Negative Design,” *American Journal of Epidemiology*, vol. 184, no. 5, pp. 354–356, 2016.
- [8] Jamie Lopez Bernal et. al., “Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant,” *New England Journal of Medicine*, vol. 385, no. 7, pp. 585–594, 2021.
- [9] GB news channel. https://twitter.com/resist_05/status/1511895388185571328, 2022. Retrieved on 04.7.2022.
- [10] M. L. Meldrum, “A brief history of the randomized controlled trial,” *Haematology/Oncology clinics of North America*, vol. 14, pp. 745–760, Aug. 2000.
- [11] Edward E. Walsh et. al., “Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates,” *New England Journal of Medicine*, vol. 383, no. 25, pp. 2439–2450, 2020.
- [12] Fernando P. Polack et. al., “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,” *New England Journal of Medicine*, vol. 383, no. 27, pp. 2603–2615, 2020.
- [13] S.J. Thomas et. al., “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months,” *New England Journal of Medicine*, vol. 385, no. 19, pp. 1761–1773, 2021.
- [14] Merryn Voysey et. al., “Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK,” *Lancet*, vol. 397, pp. 99–111, 2021.
- [15] Joseph Fraiman, Juan Erviti, Mark Jones, Sander Greenland, Patrick Whelan, Robert M. Kaplan, Peter Doshi, “Serious adverse events of special interest following mRNA vaccination in randomized trials.” <https://ssrn.com/abstract=4125239>, 2022. Retrieved on 30.6.2022.
- [16] P. D. Thacker, “Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial,” *BMJ*, vol. 375, 2021.

- [17] Radford M. Neal, "Probabilistic inference using Markov Chain Monte Carlo Methods," 1993, Technical Report CRG-TR-93-1, Department of Computer Science, University of Toronto.
- [18] John Dagpunar, *Principles of Random Variate Generation* . Clarendon Press, 1988.
- [19] Laura Whitworth et. al., "A Bayesian analysis of the association between Leukotriene A4 Hydrolase genotype and survival in tuberculous meningitis," *eLife*, vol. 10, 2021. Downloaded from <https://elifesciences.org/articles/61722> on 31.1.2021.